Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | LSS | P48449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7794136 | 0.89 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL7794135 | 0.89 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL7794133 | 0.89 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL10568279 | 0.78 | CYP1A2 (0.55) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL10568285 | 0.78 | CYP1A2 (0.55) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL25684438 | 0.78 | CYP1A2 (0.48) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL10570599 | 0.76 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL10570592 | 0.76 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTCYP2D6 | |
| SCHEMBL28287947 | 0.76 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTTCYP2C9 | |
| SCHEMBL26242235 | 0.75 | CYP1A2 (0.38) | CYP1A2LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | SLC10A1, NR1H4, HAVCR2 | CYP1A2 580/4885LMNA 506/4885MAPK1 1512/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | CYP1A2 580/4885LMNA 506/4885MAPK1 1512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.